ArunA Bio

OverviewSuggest Edit

ArunA Bio is engaged in advancing a new class of cell-free biologics, exosomes, for the treatment of central nervous system (CNS) and neurodegenerative disorders and leveraging a platform to optimize the delivery of RNAs, antibodies, genes and small molecules. Using the platform, the Company strives to improve outcomes for CNS cancers, neurodegenerative, genetic and rare diseases.

HQAthens, GA, US

Latest Updates

Employees (est.) (Jul 2020)27(+4%)
Cybersecurity ratingAMore

Key People/Management at ArunA Bio

Mark Sirgo

Mark Sirgo

Chief Executive Officer, Director
C. William Griffin

C. William Griffin

Chairman of the Board
Steven Stice

Steven Stice

Co-Founder, Chief Scientific Officer
Tracey Worthington-Stice

Tracey Worthington-Stice

Chief Operating Officer
Al Medwar

Al Medwar

Executive Vice President, Corporate and Commercial Development
Darren W. Devore

Darren W. Devore

Show more

ArunA Bio Office Locations

ArunA Bio has an office in Athens
Athens, GA, US (HQ)
425 River Rd
Athens, GA, US
184 Collins Ind Blvd suite a
Show all (2)

ArunA Bio Financials and Metrics

Summary Metrics

Founding Date


ArunA Bio total Funding

$26.9 m

ArunA Bio latest funding size

$4.5 m

Time since last funding

2 years ago

ArunA Bio investors

ArunA Bio's latest funding round in October 2019 was reported to be $4.5 m. In total, ArunA Bio has raised $26.9 m
Show all financial metrics

ArunA Bio Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

ArunA Bio Online and Social Media Presence

Embed Graph

ArunA Bio News and Updates

2021 Global Exosome Market Size, Forecast, Trials and Trends, Featuring Profiles of 107 Competitors Including Abbexa, Ltd., Abnova, Aruna Bio and Tavec Pharma

Dublin, April 22, 2021 (GLOBE NEWSWIRE) -- The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2021" report has been added to's offering.

Aruna Bio Closes $10.8 Million Common Stock Financing

Financing will support the advancement of the company’s proprietary neural exosome platform to treat neurodegenerative diseases Financing will support the advancement of the company’s proprietary neural exosome platform to treat neurodegenerative diseases

ArunA Bio Frequently Asked Questions

  • When was ArunA Bio founded?

    ArunA Bio was founded in 2003.

  • Who are ArunA Bio key executives?

    ArunA Bio's key executives are Mark Sirgo, C. William Griffin and Steven Stice.

  • How many employees does ArunA Bio have?

    ArunA Bio has 27 employees.

  • Who are ArunA Bio competitors?

    Competitors of ArunA Bio include Codiak Biosciences, Quentis Therapeutics and TCR CURE Biopharma.

  • Where is ArunA Bio headquarters?

    ArunA Bio headquarters is located at 425 River Rd, Athens.

  • Where are ArunA Bio offices?

    ArunA Bio has an office in Athens.

  • How many offices does ArunA Bio have?

    ArunA Bio has 2 offices.